Clearmind Medicine Partners with Dr. Gabor Maté to Discuss Alcohol Use Disorder and Trauma in a Special Virtual Event on February 3

A renowned speaker, and bestselling author, Dr. Gabor Maté is highly sought after for his expertise on a range of topics including addiction, stress and childhood development

TORONTO, Jan. 28, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the “Company”), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is proud to announce that as part of its “Psychedelics for Alcoholism” events series, it will host Dr. Gabor Maté, to discuss alcohol use disorder and trauma, and how Clearmind’s candidate treatment may create a clear path to dealing with trauma, at a special virtual event.

The online event will be held on February 3, 2022, commencing at 12 p.m. EST, and is open and free to all, registration required.

A renowned speaker, and bestselling author, Dr. Gabor Maté is highly sought after for his expertise on a range of topics including addiction, stress and childhood development. His four books have been translated into nearly thirty languages. Dr. Gabor Maté is a retired Vancouver physician and a member of the Order of Canada. His next work, The Myth Of Normal: Trauma, Illness and Healing in a Toxic Culture, will be published on September 13th 2022, and is available for pre-sale now through (Amazon etc.).

Dr. Adi Zuloff-Shani, Ph.D., CEO of Clearmind, commented on the announcement, “We at Clearmind are committed to creating meaningful collaborations that eventually can benefit the lives of millions of people around the world including the engagement of renowned people in our fields of research.  Partnering with the world-renowned expert, Dr. Gabor Maté, is a tremendous honor. The upcoming event will provide participants with valuable and fascinating insight regarding some of the most common mental health issues prevalent nowadays.” 

The event will be hosted by Shannon Smadella, former Miss Canada & Spokesperson for World Psychedelics Day, and will feature Adi Zuloff-Shani, PhD, Chief Executive Officer of Clearmind and Adjunct Prof. Mark Haden, Clearmind’s VP of Business Development.

Clearmind is honored to have numerous companies supporting the event, including Microdose, Psychedelic Newswire, CFN Media, Investor Brand Network, Take Back Your Power, Vallin Hypnotherapy, Insight Global, The Flying Sage, and Force Field EMF.

To learn more about Psychedelics for Alcoholism, visit the event website.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of four patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND”, the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC pink under the symbol “CMNDF”.

For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.